Development of a novel score for liver fibrosis staging and comparison with eight simple laboratory scores in large numbers of HCV-monoinfected patients

Clinica Chimica Acta

Volumn 413, Issue 21-23, 2012, Pages 1725-1730

  Attallah, Abdelfattah M ^a   Omran, Mohamed M ^a   Farid, Khaled ^b   El Bendary, Mahmoud ^b   Emran, Tarek M ^c   Albannan, Mohamed S ^a   El Dosoky, Ibrahim ^b  

^a Biotechnology Research Center of New Damietta   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

^c AL AZHAR UNIVERSITY   (Egypt)

Author keywords

Blood markers; HCV; Liver fibrosis; Score

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN;

ACCURACY; ADULT; AGE; ARTICLE; ASPARTATE TO PLATELET RATIO INDEX; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; FEMALE; FIB 4 INDEX; FIBROSIS CIRRHOSIS INDEX; FIBROSIS INDEX; FIBROSIS QUOTIENT INDEX; FIBROSIS ROUTINE TEST; FOUR ROUTINE LABORATORY BLOOD TEST; GOTEBORG UNIVERSITY CIRRHOSIS INDEX; HEPATITIS C; HUMAN; LINEAR DISCRIMINANT ANALYSIS; LIVER BIOPSY; LIVER FIBROSIS; LOK INDEX; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RELIABILITY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STAGING; THROMBOCYTE COUNT; VALIDATION STUDY;

ADULT; AGED; AREA UNDER CURVE; DISCRIMINANT ANALYSIS; HEPATITIS C, CHRONIC; HISTOLOGICAL TECHNIQUES; HUMANS; LIVER CIRRHOSIS; MIDDLE AGED;

HEPATITIS C VIRUS;

EID: 84864343511     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.06.031     Document Type: Article

References (35)

1. Alter M.J. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007, 13:2436-2441.
2. Timm J., Neukamm M., Kuntzen T., et al. Characterization of full-length hepatitis C virus genotype 4 sequences. J Viral Hepat 2007, 14:330-337.
3. Miller F.D., Abu-Raddad L.J. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc Natl Acad Sci U S A 2010, 107:14757-14762.
4. Bedossa P., Dargère D., Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-1457.
5. Pawlotsky J.M. Current and future concepts in hepatitis C therapy. Semin Liver Dis 2005, 25:72-83.
6. Grigorescu M. Noninvasive biochemical markers of liver fibrosis. J Gastrointestin Liver Dis 2006, 15:149-159.
7. Yeshua H., Oren R. Non invasive assessment of liver fibrosis. Ann Transplant 2008, 13:5-11.
8. Cadranel J.F., Rufat P., Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. Hepatology 2000, 32:477-481.
9. Poynard T., Ratziu V., Bedossa P. Appropriateness of liver biopsy. Can J Gastroenterol 2000, 14:543-548.
10. Imbert-Bismut F., Ratziu V., Pieroni L., Charlotte F., Benhamou Y., Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001, 357:1069-1075.
11. Wong J.B., Koff R.S. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med 2000, 133:665-675.
12. Martínez S.M., Crespo G., Navasa M., Forns X. Noninvasive assessment of liver fibrosis. Hepatology 2011, 53:325-335.
13. Wai C.T., Greenson J.K., Fontana R.J., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518-526.
14. Lok A.S., Ghany M.G., Goodman Z.D., et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2005, 42:282-292.
15. Islam S., Antonsson L., Westin J., Lagging M. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol 2005, 40:867-872.
16. Ohta T., Sakaguchi K., Fujiwara A., et al. Simple surrogate index of the fibrosis stage in chronic hepatitis C patients using platelet count and serum albumin level. Acta Med Okayama 2006, 60:77-84.
17. Hsieh Y.Y., Tung S.Y., Lee I.L., et al. FibroQ: an easy and useful noninvasive test for predicting liver fibrosis in patients with chronic viral hepatitis. Chang Gung Med J 2009, 32:614-622.
18. Ahmad W., Ijaz B., Javed F.T., et al. A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI). BMC Gastroenterol 2011, 11:44.
19. Vallet-Pichard A., Mallet V., Nalpas B., et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007, 46:32-36.
20. Attallah A.M., Shiha G.E., Omran M.M., Zalata K.R. A discriminant score based on four routine laboratory blood tests for accurate diagnosis of severe fibrosis and/or liver cirrhosis in Egyptian patients with chronic hepatitis C. Hepatology 2006, 34:163-169.
21. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997, 349:825-832.
22. Manning D.S., Afdhal N.H. Diagnosis and quantitation of fibrosis. Gastroenterology 2008, 134:1670-1681.
23. Friedman S.L. Liver fibrosis - from bench to bedside. Hepatology 2003, 38:S38-S53.
24. Sebastiani G., Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006, 12:3682-3694.
25. Attallah A.M., Zahran F., Ismail H., Omran M.M., El-Dosoky I., Shiha G.E. Immunochemical identification and detection of serum fibronectin in liver fibrosis patients with chronic hepatitis C. J Immunoassay Immunochem 2007, 28:331-342.
26. Attallah A.M., Mosa T.E., Omran M.M., Abo-Zeid M.M., El-Dosoky I., Shaker Y.M. Immunodetection of collagen types I, II, III, and IV for differentiation of liver fibrosis stages in patients with chronic HCV. J Immunoassay Immunochem 2007, 28:155-168.
27. Attallah A.M., Toson E.A., Shiha G.E., Omran M.M., Abdel-Aziz M.M., El-Dosoky I. Evaluation of serum procollagen aminoterminal propeptide III, laminin, and hydroxyproline as predictors of severe fibrosis in patients with chronic hepatitis C. J Immunoassay Immunochem 2007, 28:199-211.
28. Attallah A.M., Toson E.A., El-Waseef A.M., Abo-Seif M.A., Omran M.M., Shiha G.E. Discriminant function based on hyaluronic acid and its degrading enzymes and degradation products for differentiating cirrhotic from non-cirrhotic liver diseased patients in chronic HCV infection. Clin Chim Acta 2006, 369:66-72.
29. Adams L.A., Bulsara M., Rossi E., et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005, 51:1867-1873.
30. Cales P., Oberti F., Michalak S., et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005, 42:1373-1381.
31. Fahim F.A., Esmat A.Y., Hassan G.K., Abdel-Bary A. Biochemical changes in patients with combined chronic schistosomiasis and viral hepatitis C infections. Dis Markers 2000, 16:111-118.
32. Ryder S.D. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004, 53:451-455.
33. Pagliaro L., Rinaldi F., Craxi A., et al. Percutaneous blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis. A prospective, randomized trial. Dig Dis Sci 1983, 28:39-43.
34. Poniachik J., Bernstein D.E., Reddy K.R., et al. The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest Endosc 1996, 43:568-571.
35. Lackner C., Struber G., Liegl B., et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005, 41:1376-1382.